Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor-Reference-Cited by-同舟云学术

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Published:2022-12 Issue: Volume:243 Page:114714
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Sun Yin,Wang Lin,Sun Yu,Wang Jingkai,Xue Yanli,Wu Tianxiao,Yin Wenbo,Qin Qiaohua,Sun Yixiang,Wang Hanxun,Gao Yinli,Yang Huali,Zhao Dongmei,Cheng Maosheng

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference61 articles.

1. Non-mitotic functions of polo-like kinases in cancer cells;Raab;Biochim. Biophys. Acta Rev. Canc,2021

2. Emerging insights into symmetry breaking in centriole duplication: updated view on centriole duplication theory;Yamamoto;Curr. Opin. Struct. Biol.,2021

3. PLK4: a link between centriole biogenesis and cancer;Maniswami;Expert Opin. Ther. Targets,2018

4. The discovery of PLK4 inhibitors: (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents;Laufer;J. Med. Chem.,2013

5. Discovery of inhibitors of Aurora/PLK targets as anticancer agents;Qi;J. Med. Chem.,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present);Expert Opinion on Therapeutic Patents;2024-07-15

2. Therapeutic potential of targeting polo-like kinase 4;European Journal of Medicinal Chemistry;2024-02

3. Design, synthesis and antitumor activity evaluation of tetrasubstituted pyrimidine derivatives containing methyl phenyl sulfone group;Medicinal Chemistry Research;2023-07-12

4. Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer;Journal of Medicinal Chemistry;2023-06-06

5. Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia;Journal of Medicinal Chemistry;2023-02-03